Asep Medical Holdings Inc. announced the use of artificial intelligence (AI) to rapidly identify infections at increased risk of severe sepsis. The method was developed by the Hancock Lab, under the guidance of Dr. Robert E.W. Hancock, Killam Professor at the University of British Columbia (UBC), and analyzes the functional immune responses involved in sepsis to identify sets of genes that help assess whether a patient will acquire severe sepsis. This confirmatory clinical trial will precede a larger study to demonstrate the performance of SepsetERTM, the Company's sepsis diagnostic technology, and compare it to currently available sepsis tests in anticipation of filing a 510(k) submission with the FDA seeking clearance for the test as a medical device.

Asep Inc. anticipates that the 510(k) application process will be complete in First Quarter 2024, and the test should be available to hospitals soon after. AI was also used to deconvolute the extreme complexity of sepsis, which has limited treatment to date.